Last reviewed · How we verify

Propofol induced sedation

Centre Hospitalier Universitaire de Saint Etienne · Phase 3 active Small molecule Under review Quality 0/100

Propofol induced sedation is a GABA_A receptor agonist Small molecule drug developed by Centre Hospitalier Universitaire de Saint Etienne. It is currently in Phase 3 development for Sedation for medical procedures. Also known as: PIS.

Propofol induces sedation by enhancing the inhibitory neurotransmission mediated by GABA_A receptors.

Propofol is used to treat various conditions, including perioperative pain management, delirium, and lumbar radiculopathy, often in conjunction with spinal anesthesia or quadratus lumborum block. It functions as a positive allosteric modulator of the GABA-A receptor, an anion channel, which is a small molecule mechanism of action.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePropofol induced sedation
Also known asPIS
SponsorCentre Hospitalier Universitaire de Saint Etienne
Drug classGABA_A receptor agonist
TargetGABA_A receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Propofol acts as a positive allosteric modulator of the GABA_A receptor, increasing the frequency of chloride channel opening and resulting in hyperpolarization of the neuronal membrane. This leads to a decrease in neuronal excitability and an overall sedative effect. Propofol's mechanism of action is thought to be responsible for its anxiolytic, anticonvulsant, and muscle relaxant properties.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Propofol induced sedation

What is Propofol induced sedation?

Propofol induced sedation is a GABA_A receptor agonist drug developed by Centre Hospitalier Universitaire de Saint Etienne, indicated for Sedation for medical procedures.

How does Propofol induced sedation work?

Propofol induces sedation by enhancing the inhibitory neurotransmission mediated by GABA_A receptors.

What is Propofol induced sedation used for?

Propofol induced sedation is indicated for Sedation for medical procedures.

Who makes Propofol induced sedation?

Propofol induced sedation is developed by Centre Hospitalier Universitaire de Saint Etienne (see full Centre Hospitalier Universitaire de Saint Etienne pipeline at /company/centre-hospitalier-universitaire-de-saint-etienne).

Is Propofol induced sedation also known as anything else?

Propofol induced sedation is also known as PIS.

What drug class is Propofol induced sedation in?

Propofol induced sedation belongs to the GABA_A receptor agonist class. See all GABA_A receptor agonist drugs at /class/gaba-a-receptor-agonist.

What development phase is Propofol induced sedation in?

Propofol induced sedation is in Phase 3.

What are the side effects of Propofol induced sedation?

Common side effects of Propofol induced sedation include Respiratory depression, Hypotension, Bradycardia, Nausea and vomiting, Headache.

What does Propofol induced sedation target?

Propofol induced sedation targets GABA_A receptor and is a GABA_A receptor agonist.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing